CBO Urges More Research on No Surprises Act's Impact

The Congressional Budget Office (CBO) is urging more research into the No Surprises Act to better understand its impact on healthcare costs, network participation, ownership structures, and other critical areas. This call comes as the law's effectiveness in reducing surprise medical bills remains a topic of debate among policymakers, payers, and providers.

Signed into law on December 27, 2020, the No Surprises Act was designed to protect patients from unexpected medical bills by prohibiting certain out-of-network providers from balance billing. The act also introduced an independent dispute resolution (IDR) process to settle disagreements between insurers and healthcare providers over out-of-network charges.

Initially, the CBO projected that the legislation would lead to a 1% reduction in premiums charged by insurers, primarily due to anticipated decreases in both in- and out-of-network prices. However, recent data suggests that these outcomes may not be as straightforward as initially thought. The agency notes that while prices for some services with high rates of surprise billing have indeed decreased after adjusting for inflation, other factors are complicating the picture.

Providers' Advantage in IDR Cases

One significant concern is the outcome of IDR cases. According to several published reports, providers are winning more than 80% of these disputes and receiving payments that are much higher than expected, particularly in certain geographic areas. This trend has frustrated payers, who argue that it undermines the law's intended goals.

For instance, Anthem, a major health insurer, has rolled out targeted policies to penalize facilities that frequently use out-of-network providers. The company is also actively lobbying for reforms to the IDR process, aiming to make it more equitable and transparent. These efforts highlight the ongoing tension between payers and providers as they navigate the new regulatory landscape.

The high volume of filed disputes and frequent provider victories in IDR cases suggest that the current system may not be achieving its intended balance. This imbalance could lead to higher healthcare costs for both insurers and patients, potentially offsetting some of the savings anticipated by the CBO.

What Comes Next

As the debate over the No Surprises Act continues, the CBO's call for more research is a critical step toward ensuring that policymakers have the necessary data to make informed decisions. The agency's request highlights the need for a comprehensive evaluation of the law's impact on various stakeholders, including patients, providers, and payers.

Moving forward, it will be essential to gather robust evidence on how the No Surprises Act is affecting healthcare prices, network participation, and overall patient outcomes. This data can help identify any unintended consequences and inform potential adjustments to the legislation.

The CBO's call for more research also underscores the importance of ongoing dialogue between all parties involved in the healthcare system. By working together, policymakers, payers, and providers can ensure that the No Surprises Act fulfills its promise of protecting patients from surprise medical bills while maintaining a sustainable and equitable healthcare environment.